Pfizer Inc. (PFE) is seeking to add Express Scripts Inc. (ESRX) to the list of U.S. pharmacy benefits managers that won’t dispense generic Lipitor after the world’s best-selling drug loses patent protection this month.
Lipitor had $10.7 billion in sales last year, about half in the U.S. Deals made with companies such as insurer Coventry Health Care Inc. (CVH) may help Pfizer retain as much as 40 percent of users through May, said Paul Bisaro, chief executive officer at Watson Pharmaceuticals Inc. Watson is producing a generic version approved by New York-based Pfizer.
Securing that much of the market would produce sales of about $932 million in 2012, compared with $233 million if Pfizer retained just 10 percent, the amount generally seen for medicines losing patent protection, said Tim Anderson, an analyst with Sanford C. Bernstein in New York. Express Scripts provides medicines to about 90 million workers.
“We have had discussions with Pfizer,” said Brian Henry, a spokesman for St. Louis-based Express Scripts, in an e-mailed response to questions. While he declined to comment on where the talks stand, he said “Pfizer has offered similar deals in the marketplace.”
Pfizer’s deal with Bethesda, Maryland based Coventry is being overseen by Medco Health Solutions Inc. (MHS), its pharmacy benefit manager.
Under Pfizer’s agreements that are being administered by Franklin Lakes, New Jersey-based Medco and Rockville, Maryland- based Catalyst, the companies will block generic versions of Lipitor from reaching some customers until the end of May 2012, according to documents obtained by Bloomberg.
Thursday, November 17, 2011
Pfizer Strikes Pharmacy Deals to Hold Lipitor Sales - Bloomberg